Eli Lilly Alzheimer's Drug Delayed as FDA Plans Advisory Panel Meeting
The timing of the agency’s expected action on the donanemab drug would be postponed beyond the first quarter, the company said.
The timing of the agency’s expected action on the donanemab drug would be postponed beyond the first quarter, the company said.
Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.